JY
SVA

Jeff Yass’s Sinovac Biotech, Ltd SVA Stock Holding History

Jeff Yass’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,500
Closed -$87K – 10653
2018
Q4 		$87K Sell
12,500
-24,100
-66% -$176K ﹤0.01% 8282
2018
Q3 		$281K Sell
36,600
-13,900
-28% -$100K ﹤0.01% 7608
2018
Q2 		$377K Buy
+50,500
New +$397K ﹤0.01% 7392
2014
Q4 		– Sell
-12,000
Closed -$58K – 10710
2014
Q3 		$58K Sell
12,000
-81,200
-87% -$436K ﹤0.01% 9197
2014
Q2 		$526K Buy
93,200
+64,100
+220% +$389K ﹤0.01% 7377
2014
Q1 		$210K Buy
29,100
+18,500
+175% +$122K ﹤0.01% 8162
2013
Q4 		$65K Sell
10,600
-1,700
-14% -$10.2K ﹤0.01% 8747
2013
Q3 		$74K Buy
+12,300
New +$58.8K ﹤0.01% 8171

Other funds holding SVA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $9.13B AUM 34.49% 1-Year Est. Return

Jeff Yass's SVA Position: Q2 2026 in Review

Jeff Yass held its Sinovac Biotech, Ltd (SVA) position steady in Q2 2026 at 16,430 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #12462.

Jeff Yass first reported a position in SVA in Q4 2013 and has held it in 38 quarters since. The position peaked at $402K in Q1 2018. 29 funds tracked by Wall St. Rank hold SVA as of Q2 2026.

  • Jeff Yass held 16,430 shares of Sinovac Biotech, Ltd worth $106K as of Q2 2026.
  • Jeff Yass left its Sinovac Biotech, Ltd share count unchanged in Q2 2026.
  • Sinovac Biotech, Ltd made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12462 holding.
  • Jeff Yass first reported a position in Sinovac Biotech, Ltd in Q4 2013 and has held it in 38 quarters since.
  • Jeff Yass's Sinovac Biotech, Ltd position peaked at $402K in Q1 2018.
  • 29 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.